Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CosmoCol Half is an osmotic laxative marketed by Stirling Anglian Pharmaceuticals for the treatment of chronic constipation and faecal impaction. It is a combination formulation consisting of macrogol 3350 (polyethylene glycol) and a specific blend of electrolytes, including sodium chloride, sodium bicarbonate, and potassium chloride. The mechanism of action involves macrogol 3350 acting as an osmotic agent that binds water in the gastrointestinal tract, thereby increasing stool volume and softening consistency to promote bowel movements. The electrolyte components are included to ensure that there is no net gain or loss of water, sodium, potassium, or bicarbonate from the body during the laxative process. CosmoCol Half provides a lower dose of active ingredients per sachet compared to the standard CosmoCol formulation, allowing for more precise dose titration in various patient populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol 3350 + sodium chloride + sodium bicarbonate + potassium chloride (Stirling Anglian Pharmaceuticals).